title: Oral ixazomib maintenance therapy in multiple myeloma.
abstract: Continuous therapy has proven to be an effective therapeutic strategy to improve the outcome of both young and elderly multiple myeloma patients. Remarkably, lenalidomide and bortezomib showed to play a crucial role in this setting due to their safety profile allowing long-term exposure. Ixazomib, the first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may be an attractive option for maintenance therapy. Here we address the issue of maintenance therapy as part of a therapeutic approach of multiple myeloma patients focusing on the potential role of ixazomib.
authors.affiliation: a Azienda Ospedaliero-Universitaria , Ospedali Riuniti di Ancona , Ancona , Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Offidani
authors.affiliation: b Dipartimento di Medicina, UOC Medicina , Fabriano , Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Corvatta
authors.affiliation: a Azienda Ospedaliero-Universitaria , Ospedali Riuniti di Ancona , Ancona , Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Gentili
authors.affiliation: a Azienda Ospedaliero-Universitaria , Ospedali Riuniti di Ancona , Ancona , Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Maracci
authors.affiliation: a Azienda Ospedaliero-Universitaria , Ospedali Riuniti di Ancona , Ancona , Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Leoni
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001896:Boron Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005998:Glycine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D061988:Proteasome Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D001896:Boron Compounds; D061988:Proteasome Inhibitors; C548400:ixazomib; D005998:Glycine
keywords: Ixazomib; maintenance; minimal residual disease; multiple myeloma; proteasome inhibitors